BlueScope left investors disappointed this morning with a 64% lower net profit

Nick Sundich Nick Sundich, February 20, 2023

Of this morning’s 1HY23 results, Bluescope (ASX:BSL) was the one that left investors the most disappointed, if the ~7% share price decline is any guide. The company’s net profit and EBIT both declined by over 60%, missing analysts expectations. 

 

 

No time to do stock research, but you still want to invest?

 
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 
Bluescope’s EBIT and net profit fell by over 60%

1HY23 was a difficult market for steel with weather related disruptions in building and construction activity. 

Although Bluescope’s revenue was only down 1.2% from 12 months ago (at $9.3bn), the company’s EBIT and net profit came in at 60% lower than 12 months ago – at $834.4m and $598.8m respectively. The company’s ROIC also fell from 43.7% to 23.4%. 

On a more positive note, the company’s net cash grew $367m to $606m and its free cash flow (operaitng cash flow less capex) was up $63m to $751m. Its interim dividend was unchanged at 25cps, representing a 2.7% yield on an annualised basis. 

Shares fell by over 7% in this morning’s trade, the most of any company releasing 1HY23 results. 

 

Bluescope (ASX:BSL) share price chart, log scale (Source: TradingView)

 

Bluescope says the long-term outlook remains positive

Despite the negative results, Bluescope told shareholders it was well positioned for the long-term.

The company said the global green revolution was driving demand for steel as a critical input towards particular types of infrastructure, particularly renewable energy and e-commerce infrastructure.

It also noted consolidation and rationalisation in the US steel industry and a focus on emissions reduction by China’s steel industry supported supply-side discipline.

 

Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
 
With price targets, buy ranges, stop loss levels and Sell alerts too.

 

GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

best stocks

5 Best Stocks Under $100 To Buy Now

If you’re new to investing and don’t have a lot of money to start with, will you be missing out…

Telix Pharmaceuticals on the Nasdaq

Telix Pharmaceuticals (ASX:TLX): Is there further upside to be excited for in FY25?

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…

like for like sales

Like for like sales: What does it mean and why do retailers use that creative term?

ASX retailers often use ‘like for like’ sales in addition to total sales. It is most common for companies that…